Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study

Amgen (AMGN) PT Raised to $202 at BMO Capital Amid Positive Repatha Data

February 3, 2017 6:53 AM EST

BMO Capital raised its price target on Amgen (NASDAQ: AMGN) to $202.00 (from $197.00) while maintaining a Outperform rating following positive Repatha CV outcomes data

Analyst M. Ian Somaiya commented, "Addition of CV outcomes data to the Repatha label and launch of erenumab for migraine... More